Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00038428 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of TLK286 in Platinum Resistant Advanced Epithelial Ovarian Cancer
A Phase 2 study, sponsored by Telik.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT00038428 is a Phase 2 study that has completed, run by Telik. The registered enrollment target is 40 participants.
The verdict
NCT00038428, a Phase 2 study, has completed, sponsored by Telik.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the effectiveness and safety of TLK286 given intravenously once every week in the treatment of patients with advanced ovarian cancer that is resistant to platinum-based chemotherapy.
Interventions
- DRUG TLK286
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2001-06 |
| Est. Completion | 2005-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00038428
The ClinicalTrials.gov registry entry for NCT00038428 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Telik, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TLK286 is the first listed.
NCT00038428 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00038428 about?
NCT00038428 is a clinical study titled "Phase 2 Study of TLK286 in Platinum Resistant Advanced Epithelial Ovarian Cancer". The purpose of this study is to determine the effectiveness and safety of TLK286 given intravenously once every week in the treatment of patients with advanced ovarian cancer that is resistant to platinum-based chemotherapy.
What is the current status of trial NCT00038428?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2001-06. Estimated completion is 2005-07.
What interventions are being tested in trial NCT00038428?
The interventions under investigation include: TLK286 (DRUG).
Who is sponsoring clinical trial NCT00038428?
This trial is sponsored by Telik, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.